CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
Palantir Stock Jumps After Strong Q4 Earnings Beat and Upbeat 2026 Revenue Forecast 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Nintendo Shares Slide After Earnings Miss Raises Switch 2 Margin Concerns 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
Qantas to Sell Jetstar Japan Stake as It Refocuses on Core Australian Operations 
Novo Nordisk Warns of Profit Decline as Wegovy Faces U.S. Price Pressure and Rising Competition 
AMD Shares Slide Despite Earnings Beat as Cautious Revenue Outlook Weighs on Stock 
CK Hutchison Unit Launches Arbitration Against Panama Over Port Concessions Ruling 
Australian Scandium Project Backed by Richard Friedland Poised to Support U.S. Critical Minerals Stockpile 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
Instagram Outage Disrupts Thousands of U.S. Users 
Anthropic Eyes $350 Billion Valuation as AI Funding and Share Sale Accelerate 
Boeing Signals Progress on Delayed 777X Program With Planned April First Flight 
Sam Altman Reaffirms OpenAI’s Long-Term Commitment to NVIDIA Amid Chip Report 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
KISSIMMEE, Fla., Aug. 29, 2017 -- Kerecis will present key findings of research into fish-skin treatments for the care of severely wounded service members during the 2017 Military Health System Research Symposium. The research was funded by the Office of Naval Research (ONR) and the U.S. Army Medical Research and Materiel Command.
The goal of the research is to establish the efficacy of the Kerecis Omega3-rich fish skin to cover limbs injured or lost by explosives, and for dura repair after head trauma. The fish skin will be used to cover limb injuries from the time the medic first treats the service member until the patient is in a full-service hospital and after debridement as a skin-graft substitute. The dura-repair fish-skin technology will be used in a combat hospital setting where severe head traumas are treated.
The need for improved remedies for severe wounds and head trauma has intensified with the increased amount of insurgent warfare. Head traumas and death rates related to burn and blast injuries in such warfare are higher than in conventional battlefield conditions, partially because of the extensive use of improvised explosive devices.
The Kerecis Omega3 fish skin is already FDA approved for treating burns and other wounds. “The trial results presented on the conference literally put our fish-skin-based technology on the ‘front line’ for treating more serious trauma and will help us expand our regulatory approvals at the FDA to new indications. Kerecis is committed to developing better remedies for injured U.S. service members, and to providing good research value for the DoD,” explained G. Fertram Sigurjonsson, CEO, Kerecis.
About Kerecis Omega3 in the Treatment of Wounds
“Cadaver skin has been the preferred initial treatment for severe burns,“ explained Dr. Hilmar Kjartansson, Medical Director at Kerecis. “It is commonly used in hospitals, where skin grafting is the preferred way to treat stabilized burn wounds. However, on the battlefield or in other combat conditions, it’s not practical to use cadaver skin or skin grafts.”
The research capitalizes on the characteristics of the FDA-approved Kerecis Omega3 Wound product, intact fish skin that is rich in naturally occurring Omega3 polyunsaturated fatty acids.
About Kerecis Omega3 in the Treatment of Head Trauma
“The dural membrane surrounds the brain and contains the brain fluids,” explained Dr. Kjartansson. “In severe head trauma the dural membrane is damaged and needs to be restored to contain the brain fluids. At the conference we will present the results of a large animal trial where the efficacy of the Kerecis Omega3-rich fish skin is established as a dura patch.”
Research Presentations
Tuesday, August 29, 2017, at 15:30, in the TBI Treatment & Emerging Care breakout session, Dr. Ingvar Olafsson will present the results of a large ovine study where Kerecis Omega3 fish skin was used successfully to treat dural defects. The results show minimal inflammatory response, good tissue integration and neodura formation. Dr. Olafsson is a neurosurgeon at Landspitali University Hospital in Iceland.
Wednesday, August 30, 2017, at 08:30, in plenary session A, Lt. Col. SLA Jeffery, RAMC, will present results of a comparative burn study where fish skin and cadaver skin were compared in a porcine model. Lt. Col. SLA Jeffery is a burns and plastic surgeon consultant at the Royal Centre for Defence Medicine, The Queen Elizabeth Hospital, Birmingham, UK.
About the Military Health System Research Symposium
The MHSRS, the Department of Defense’s premier scientific meeting, is a venue for communicating and discussing new scientific knowledge resulting from military-unique research and development. The annual event is the only military or civilian meeting that focuses specifically on the unique medical needs of the Warfighter. MHSRS is sponsored by the Assistant Secretary of Defense for Health Affairs.
About Kerecis
Kerecis develops regenerative technologies based on fish skin and Omega3 polyunsaturated fatty acids. The technology is patented in the United States and multiple other countries. The initial Kerecis product, Kerecis Omega3 Wound, has been approved by the FDA and European regulatory authorities for wound healing. The Kerecis technology has also been approved for use as a surgical buttress (Kerecis Omega3 SecureMesh) and as a treatment for burn wounds (Kerecis Omega3 Burn). Production takes place in the Kerecis manufacturing facilities in Iceland. For more information, visit www.kerecis.com. Distributor inquiries are welcome.
Contact: Kay Paumier Communications Plus 408-370-1243 [email protected]
